Preliminary Results for Year Ended 30 June 2025

AI SummaryClose X

Sareum Holdings PLC reported a loss before tax of £3.06 million for the year ended 30 June 2025. The company's cash reserves increased to £3.5 million, up from £1.5 million the previous year, bolstered by successful fundraises. Administrative expenses, including R&D, totaled £3.38 million, with R&D spending specifically at £2.07 million. R&D tax credits received during the period amounted to £1.2 million, compared to £0.8 million in the prior year. The company renegotiated improved economic terms for SRA737, securing 63.5% of future revenues compared to the previous 27.5%. A preclinical toxicology study for SDC-1801 was discontinued due to findings considered unrelated to the drug, and discussions are underway to restart it.

Disclaimer*

UK 100

Latest directors dealings